NCT07472387Not yet recruiting
Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas
Source: ClinicalTrials.gov · Last updated 16 Mar 2026
Brief summary (registry, in English)
Glioblastoma (GBM) is the most common and most aggressive primary brain cancer in adults. GBM is more common in men than in women, with a male-to-female ratio of 1.6. Furthermore, being male is associated with a poorer prognosis. These data suggest that sex and/or sexual hormones and more specifically androgens may play a role in the initiation, the growth, and the resistance to treatments of GBM.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 16 Feb 2026
- Start date
- Apr 2026
- Primary completion date
- Apr 2030
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Glioblastoma
- NCT number
- NCT07472387
What you commit to
- Study type: Interventional
- Planned participants: 40
- From Apr 2026 to the primary completion date, Apr 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Active infection at the time of sampling or within the previous 14 days
- Patients treated with corticosteroids
Other illness
- Active immune disorders
Other
- Known patients with low-grade glioma that has undergone anaplastic transformation
- Patients participating in interventional research
- Patients under legal protection, guardianship, or conservatorship.
- Pregnant or breastfeeding women
- Individuals under AME
Who the study is looking for
- Patients aged ≥18 and ≤55
- Newly diagnosed GBM
- Surgery with complete or incomplete resection
- Eligible for chemoradiotherapy
- No active immune disorders
- Supratentorial location on MRI and no signs of meningeal dissemination
- Tumor sample (taken as part of treatment) available for study (fresh frozen tissue)
- Patient informed and consented to participate in the study
- Affiliation with a social security system or beneficiary
Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Neuro-oncology department, Pitié Salpêtrière hospital Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.